Chinanews.com, Nanning, September 23 (Reporter Lin Hao) "Guangxi is the main undertaking site for the eastward migration of mulberry to the west. The sericulture industry is developed and the mulberry tree planted area is large. At the same time, Guangxi is adjacent to ASEAN countries by land and sea and has rich plant resources and natural resources. Drug development potential is huge. We will take the opportunity of mulberry branch alkaloid products to be approved and settled in Guangxi to promote the gathering of healthy enterprises for comprehensive development of mulberry resources and help the high-quality development of Guangxi's biomedical industry." Professor Liu Yuling of the Chinese Academy of Medical Sciences said on the 23rd.
On the same day, the "Investment Promotion Seminar for Banks and Enterprises Helping the High-quality Development of Guangxi Biopharmaceutical Industry" jointly organized by the People's Government of Guangxi Zhuang Autonomous Region and China Pharmaceutical Enterprise Management Association, and undertaken by Guangxi Market Supervision Bureau and Guangxi Investment Promotion Bureau was held in Nanning City. Participants The guests shared the development opportunities of Guangxi's biopharmaceutical industry and reached 25 contracted projects with a total intention of 24.8 billion yuan in investment.
Xiu Laigui, chairman of the National Federation of Industry and Commerce Pharmaceutical Chamber of Commerce and chairman of the Amendment Pharmaceutical Group, is also optimistic about the development prospects of Guangxi's biopharmaceutical industry.
He said that Guangxi has a unique endowment of Chinese medicine resources and a well-developed Chinese herbal medicine planting industry. At present, with the introduction of a series of policies supporting the Chinese medicine industry, it will become a new investment depression for Chinese medicine companies.
Xiu Laigui introduced that at present, the member companies of the Pharmaceutical Chamber of Commerce of the All-China Federation of Industry and Commerce have deployed multiple projects in Nanning, Wuzhou, Qinzhou, Guigang, and Qinzhou. Next, a biomedical research and development center will be established in Nanning.
Zhu Weifeng, President of Jiangxi University of Traditional Chinese Medicine, stated that Guangxi Traditional Chinese Medicine has a long history of development of Zhuangyao medicine, with a wide variety of Chinese herbal medicines, rich clinical experience in Chinese medicine, and a sound scientific research and talent training system, which has laid a good foundation for the development of the biomedical industry. Negotiate with all parties in Guangxi, and strive to carry out project cooperation in multiple fields.
Li Bin, vice chairman of the Guangxi Zhuang Autonomous Region, said in his speech that Guangxi is known as the "natural medicine bank", "resource gene bank" and "hometown of Chinese medicinal materials". The planting area of medicinal materials accounts for about one-fifth of the country. It is also an important channel for the import of Chinese medicinal materials from ASEAN countries.
In recent years, Guangxi has taken biomedicine as a key industry to cultivate and develop, set up a biomedical industry investment guide sub-fund, focused on the industrial chain, value chain, and innovation chain to attract investment accurately, and promoted a group of leading companies such as Huaxing Pharmaceutical and Daan Innovation Valley. Coming to develop, we will strive to achieve the goal of 100 billion yuan in biomedicine.
Li Bin hopes that the majority of Chinese medicine companies will join hands with Guangxi to accelerate industrial development, build a regional biomedical innovation center, promote the development of the biomedical industry in the direction of innovation, technology, scale, refinement, and diversification, and promote biotechnology and medical health. The cross integration of technology and information technology, promote disease diagnosis and treatment technologies and innovative medical products suitable for rural and community grassroots levels, and optimize the supply of products and services in the field of health and health.
Lu Wanqing, deputy director of Guangxi Investment Promotion Bureau, made an investment promotion for Guangxi's biomedicine industry. He introduced that Guangxi's biomedicine industry is currently in a stage of accelerating development. There are more than 1,000 key biomedical companies. In the next step, the biomedical industry will be deeply cultivated. At the end of the "14th Five-Year Plan" period, the concentration of the biopharmaceutical industry, market brand, independent innovation and talent team will be established in the western region. The comparative advantage.
(over)